Advances in lipid-lowering therapy through gene-silencing technologies

Keyphrases

• Cardiovascular Disease 100%
• Lipoproteins 100%
• Lipid-lowering Therapy 100%
• Gene Silencing 100%
• Acute Pancreatitis 66%
• Adverse Effects 66%
• Plasma Parameters 33%
• Plasma Lipoproteins 33%
• Clinical High Risk 33%
• New Therapies 33%
• RNA Transcripts 33%
• Long-term Safety 33%
• Injection Site Reaction 33%
• Small Interfering RNA (siRNA) 33%
• Target Molecule 33%
• Drug Dosing 33%
• Liver Cells 33%
• Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) 33%
• Protein Production 33%
• Protein Drug 33%
• Antisense Oligonucleotides 33%
• Unmet Medical Need 33%
• Lipoprotein Levels 33%
• Triglyceride-rich Lipoproteins 33%
• Flu-like 33%
• Remnant Lipoproteins 33%
• Treatment Opportunity 33%
• Blood Platelet Count 33%
• Disease Reduction 33%
• ANGPTL3 33%
• APOC3 33%
• Lipoprotein Production 33%
• Orphan Indication 33%
• RNA Technology 33%
• Gene Silencing Therapy 33%

Biochemistry, Genetics and Molecular Biology

• Lipoprotein 100%
• Lipid 100%
• Gene Silencing 100%
• Blood Level 20%
• Lipoprotein Blood Level 20%
• Messenger RNA 20%
• Low Drug Dose 20%
• Oligonucleotide 20%
• Antisense 20%
• PCSK9 20%
• Small Interfering RNA 20%
• Platelet Count 20%
• Triglyceride-Rich Lipoprotein 20%
• Targeting Protein 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Lipoprotein 100%
• Cardiovascular Disease 50%
• Acute Pancreatitis 33%
• Adverse Event 33%
• Triacylglycerol 16%
• Lipoprotein A 16%
• Injection Site Reaction 16%
• Drug Dose 16%
• Flu Like Syndrome 16%
• Small Interfering RNA 16%
• Antisense Oligonucleotide 16%